Cinnamon supplements and type 2 diabetes: what lower glucose readings can tell us
Table of Contents
A cinnamon bottle can sound persuasive when the label points to a meta-analysis. One published in Nutrition Reviews in 2025 did find lower average glucose measurements in people with type 2 diabetes who took cinnamon in randomized trials. But a lower blood-test number over a few months isn’t the same thing as a proven diabetes treatment - and it doesn’t tell you what a capsule on a store shelf will do for you.
The distinction matters if you’re already managing type 2 diabetes with medication and regular glucose checks. There’s a real research signal to examine here. There’s also enough disagreement and product uncertainty to make a shopping recommendation the wrong takeaway.
And if you’re considering a capsule, don’t change prescribed treatment or stop monitoring your glucose. Bring the exact product label and your medication list to a clinician or pharmacist first: NCCIH cautions that supplements can interact with diabetes treatment, and the ADA notes a possible low-glucose concern with some supplement ingredients. That isn’t a measured risk for every cinnamon product.
What the pooled trials measured #
The Nutrition Reviews authors combined 28 randomized trials involving 3,054 enrolled adults with type 2 diabetes. Participants were followed for 30 to 120 days; the authors’ literature search ended in November 2022, although the paper appeared online in 2024 and in a 2025 print issue. Its central outcomes were metabolic biomarkers, including fasting glucose, glucose after a meal and HbA1c - not observed rates of diabetic complications. Read the review abstract.
The pooled fasting-glucose estimate favored cinnamon by 15.26 mg/dL compared with controls. That number is an average across studies, not a forecast for a person taking a particular supplement. The trials varied markedly: the reported I² statistic was 88% for fasting glucose, 100% for post-meal glucose and 94% for HbA1c. In plain English, the results differed enough between studies that the pooled number needs more caution than the label headline gives it. The original authors reported a favorable HbA1c result, but a later reanalysis didn’t find a statistically significant difference for that comparison. So a lower fasting-glucose average shouldn’t be read as a settled HbA1c benefit. Source: de Moura and colleagues.
So what does an HbA1c shift tell us? It’s a measure of longer-term blood-glucose exposure, useful in diabetes care. It isn’t itself a count of heart attacks, kidney disease or other complications prevented by cinnamon. These short trials don’t establish that cinnamon changes those outcomes, and they don’t show whether any biomarker difference lasts for years. The older Cochrane review likewise reported no trial data on quality of life, morbidity or mortality in its study set.
Another 2025 analysis read the HbA1c result differently #
There’s an awkward detail worth keeping in the story. A 2025 umbrella review reanalyzed overlapping cinnamon meta-analyses. When its authors reanalyzed the Nutrition Reviews HbA1c comparison, their result was not statistically significant; across 12 HbA1c review comparisons, they rated four as weak evidence and eight as nonsignificant. Those are comparisons between reviews, not 12 fresh sets of randomized people. The reanalysis doesn’t prove the first authors fabricated a result. It does make a confident claim that cinnamon reliably lowers HbA1c hard to defend.
And this isn’t just a new-versus-old-paper argument. A 2012 Cochrane assessment also found no significant HbA1c difference, but it examined fewer, older trials and a broader diabetes population. It can’t automatically overrule a later type-2-specific synthesis. What the three assessments tell you, taken together, is more modest: some pooled short-term markers look favorable, while the HbA1c conclusion is sensitive to which evidence and methods are used. NCCIH’s assessment still describes diabetes benefit as unclear.
A trial capsule isn’t your kitchen cinnamon #
What exactly went into those trials? From the accessible review abstract, we can’t map every preparation to its cinnamon species, plant part, extraction method, co-ingredients or coumarin content. That’s not a small technicality. NCCIH notes that research often doesn’t clearly identify the species or plant part used. So a pinch of spice in coffee can’t be treated as the tested intervention, and the word “cinnamon” on a retail bottle doesn’t establish that it matches the trials either.
Cassia and Ceylon also shouldn’t be collapsed into one supposedly interchangeable product. Cassia can contain variable amounts of coumarin, a substance that raises concern with prolonged high intake in susceptible people, particularly those with liver disease; Ceylon tends to contain only traces, not a guaranteed zero. That’s a safety distinction supported by NCCIH, not proof that Ceylon works better for diabetes. The review’s capsule and lower-intake subgroup findings aren’t instructions for choosing a dose or species. See the reported subgroups.
A later 12-week trial tested a specified Ceylon extract in people recruited by LDL-cholesterol eligibility, rather than only people with type 2 diabetes. It found a fasting-glucose signal but no statistically significant HbA1c difference. Published in January 2025, it came after the meta-analysis’s 2022 search cutoff and wasn’t one of its trials. The study was industry-funded, and 127 of 150 randomized participants were assessed at 12 weeks. Those details matter when interpreting the measured result; the study doesn’t license a claim about ordinary Ceylon spice.
If you take diabetes medication, keep the decision practical #
Cinnamon used as an ordinary food spice is generally a different proposition from taking larger amounts as a supplement. NCCIH considers culinary amounts likely safe; larger or prolonged intake can bring digestive or allergic problems, and coumarin exposure matters with some cassia products, especially if you have liver disease. Pregnancy and breastfeeding need their own caution: NCCIH says larger-than-food amounts of Ceylon cinnamon are unsafe during pregnancy and that the safety of larger amounts during breastfeeding isn’t well understood. This isn’t a reason to fear a normal sprinkle on food.
But if you’re considering a capsule, bring the exact product label and your medication list to your diabetes clinician or pharmacist. NCCIH warns that supplements can interact with diabetes treatment, and the American Diabetes Association’s patient guidance cautions that some ingredients can intensify medication effects, including low blood glucose. Those broad cautions aren’t a measured interaction rate for every cinnamon product or every medicine. They’re a good reason not to self-adjust prescribed treatment or stop your glucose monitoring. Kidney disease, liver disease, pregnancy, breastfeeding or a complicated medication regimen all make an individual review more pressing; AMZ has more on supplement risks when diabetes and kidney disease overlap. If you suspect a significant low-glucose episode or unexpected changes, seek medical advice promptly rather than trying to fix the regimen with more spice.
A “cures diabetes” or “replace your pills” pitch should set off alarms. The FDA warns about products illegally marketed as diabetes treatments; neither a pooled biomarker estimate nor a natural-sounding label is approval as a diabetes drug.
Bottom line #
The 2025 meta-analysis is worth reading, not waving away: it found favorable short-term glucose-marker averages in its pool. Yet the between-study variation, a conflicting HbA1c reanalysis and the missing bridge from trial preparation to retail bottle limit what you can infer. There is no demonstrated reduction in diabetes complications in the cited review, and no basis here for replacing established care. If cinnamon is part of your diet, enjoy it as food. If a supplement is the question, make it a conversation about that particular product and your existing treatment - not a bet on a pooled number.
For a wider survey than this single cinnamon analysis, see AMZ’s review of herbs for type 2 diabetes.